PBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prestige Consumer Healthcare Inc (PBH) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks clear positive catalysts, has weak financial performance, and shows neutral technical indicators. While hedge funds are buying, insider selling and lack of recent news or significant events make this a hold rather than a buy.
The MACD is negative and expanding (-0.121), indicating bearish momentum. RSI is neutral at 41.167, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 68.919 with support at 67.188 and resistance at 70.649, showing limited upside potential in the short term.
Hedge funds are increasing their buying activity significantly (+622.44% last quarter).
Insiders are selling heavily (+291.04% last month). Financial performance has deteriorated with YoY declines in revenue (-2.37%), net income (-23.49%), and EPS (-20.49%). No recent news or event-driven catalysts. Analysts have lowered price targets and have mixed ratings, with some suggesting the stock is range-bound.
In Q3 2026, revenue dropped to $283.4M (-2.37% YoY), net income fell to $46.7M (-23.49% YoY), and EPS declined to $0.97 (-20.49% YoY). Gross margin remained relatively stable at 53.7% (-0.13% YoY). Overall, financials indicate a weakening growth trend.
Recent analyst ratings are mixed. Canaccord lowered the price target to $86 from $88 but maintained a Buy rating, citing supply issues. Jefferies lowered the price target to $66 from $70 with a Hold rating, citing weak U.S. OTC trends and lack of catalysts. Analysts generally see limited upside without a significant event like M&A.
